Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23

Southwest Gas Hlds

Billionaire investor Carl Icahn (Trades, Portfolio) disclosed his firm's first-quarter equity portfolio earlier this month.

Carl Icahn Buys Activist Target Illumina, Adds to Southwest Gas Stake

Data also shows that current standard-of-care testing for cancer patients falls short in multiple ways SAN DIEGO , May 30, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling (CGP) for oncology patients, which will be presented at the American Society of Clinical Oncology's Annual Meeting June 2–6 in Chicago. In addition to the real-world study data, Illumina, along with study collaborators, will also present on findings that expose gaps in current standard-of-care and unmet needs for cancer patients.

Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing

Illumina shareholders re-elect eight of nine Illumina directors SAN DIEGO , May 25, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina director nominees – Francis deSouza, Robert Epstein, MD, Frances Arnold, PhD, Caroline Dorsa, Scott Gottlieb, MD, Gary Guthart, PhD, Philip Schiller, and Sue Siegel, as well as Andrew Teno, to the Board of Directors. The Board thanks John Thompson for his board tenure and extraordinary leadership.

Illumina announces preliminary results of annual meeting

Carl Icahn secured a seat on Thursday for one of his three nominees to the board of gene sequencing machine maker Illumina Inc , a partial victory for the activist investor who is struggling to defend his own company from a shortseller attack.

Icahn wins Illumina board seat as he struggles to battle shortseller

Illumina Inc. ILMN, -12.05% shareholders voted Thursday to elect one of activist investor Carl Icahn's nominees to its board, and voted against the re-election of company Chairman John Thompson, according to media reports on Thursday. The genomics company has been engaged in a proxy battle with Icahn since March, who was seeking to unseat its chairman and chief executive and add three of his own candidates to the board.

Illumina shareholders vote to elect one of Carl Icahn's candidates to its board after proxy fight

Shareholders selected one of the activist investor's picks, who will replace on the board a director who had served as Illumina's chairman.

Icahn Nominee Elected to Illumina's Board

Carl Icahn has accused Illumina's management and board of poor oversight, particularly with regard to the company's acquisition of cancer test maker Grail.

Illumina shareholders vote to install Carl Icahn board nominee, oust chair

ILMN trades at a higher valuation of 7.3x trailing revenues, compared to 4.6x for TMO, partly due to its financial position.

Is Illumina Stock A Better Pick Over TMO?

Activist investor Carl Icahn is seeking to unseat Illumina's chairman and its CEO, and put three of his own people on the company's board.

Icahn vs. Illumina: The CEO's Job—and Icahn's Reputation—Are on the Line

Activist investor Carl Icahn is set to win enough Illumina Inc shareholder support to install at least one of his three nominees to the gene sequencing machine maker's board, two people familiar with the matter said on Wednesday.

Exclusive: Icahn poised to win at least one seat on Illumina's board -sources

ST. LOUIS , May 24, 2023 /PRNewswire/ -- Pluton Biosciences, a startup leveraging the power of microbes to create cost-effective innovative solutions that address sustainability challenges facing agriculture, announces the close of a $16.5 M Series A funding round. The round was co-led by Illumina Ventures and RA Capital, with participation from existing investors Fall Line Capital, The Grantham Foundation, and First In Ventures, as well as new investors Wollemi, Radicle Growth (first investment from their second fund), and iSelect.

Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change

Despite a short seller's accusations that his company has inflated its asset prices, Carl Icahn's effort to shake up Illumina's board is still very much in the interest of shareholders.

Icahn Is No Saint, but Illumina Can Still Use a Flawed Savior

The legendary activist, whose own company is under attack, has launched a proxy contest for three seats on the gene-sequencing giant's board, which is mired in a messy acquisition. The stakes are high for both.

A Wounded Carl Icahn Makes His Play at a Struggling Illumina

Carl Icahn (Trades, Portfolio) is one of the most iconic activist investors or “corporate raiders” that has ever existed. Despite being 87 years old, he is still very active in the market.

Carl Icahn Dives Into Activist Investment Illumina

Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.

Illumina (ILMN) Progresses in Pathogen Genomic Technologies

Board Chair John Thompson issues letter to Illumina shareholders ahead of the company's Annual Meeting on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time) Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nominees For more information, visit www.IlluminaForward.com SAN DIEGO , May 18, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter from Board Chair John Thompson. In his letter, Mr.

Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees

SAN DIEGO , May 16, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today recognized the progress and impact of genomic technologies on pathogen preparedness and response. Following the boost in sequencing infrastructure and capabilities driven by the COVID-19 pandemic, today genomic technologies are enabling public health agencies and health care systems to better prepare for, and respond to, pathogenic threats.

Illumina's genomic technologies enable better pathogen preparedness and response

Icahn Enterprises

Illumina's director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and Medco-UBC Leading proxy advisory firm ISS has recommended Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein Icahn's associates bring ZERO relevant experience and ZERO independence Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nominees Annual Meeting will be held virtually on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time) For more information, visit www.IlluminaForward.com SAN DIEGO , May 15, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter outlining the purpose-built mix of skills Illumina's nominees bring to the Board compared to Carl Icahn's unqualified associates, each of whom lack relevant experience and independence. Institutional Shareholder Services ("ISS"), a leading independent proxy voting and corporate governance advisory firm, recommends Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein.

Illumina sends letter to shareholders detailing why Illumina's nominees far outmatch Icahn's slate in skills and experience

SAN DIEGO , May 12, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Institutional Shareholder Services ("ISS"), a leading independent proxy voting and corporate governance advisory firm, recommends Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein. Illumina's Annual Meeting is scheduled to be held on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time).

Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote "FOR" Eight of Illumina's Highly Qualified Director Nominees

Illumina is led by its world-class Board members and has best-in-class governance practices Carl Icahn's recently released "plan" demonstrates his lack of understanding of both Illumina and the genomics industry Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nominees Annual Meeting will be held virtually on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time) For more information, visit www.IlluminaForward.com SAN DIEGO , May 8, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter highlighting the strength of its Board and noting that Carl Icahn's "plan" for Illumina is sloppy and uninformed. Illumina's Board of Directors urges shareholders to protect their investment and future of the company by voting the WHITE proxy card today FOR all nine of the company's highly qualified director nominees and not for Carl Icahn's unfit three nominees.

Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's "Plan"

Bionano Genomics

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader.

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

Illumina announced a downbeat set of earnings for its fiscal 2023 first quarter. The company received more than 200 orders for its new NovaSeq X instrument from customers in almost 30 countries.

Why Illumina Fell 11.6% in April

The phrase, “I'm from the government and I'm here to help” has a well-deserved reputation as a terrifying phrase, but for medical researcher Illumina Inc. NASDAQ: ILMN, which specializes in DNA sequencing, government meddling could actually end up helping shareholders.

Will Forced Divesture Of Grail Boost Illumina Shareholder Value?

ChargePoint Holdings

Nuuve

Penn Entertainment

B2Gold

National Fuel Gas

Wyndham Hotels & Resorts Inc

With the labor market expanding and inflation receding, it's time to identify breakout growth stocks with significant potential. As the U.S. economy continues to defy the odds with its resiliency, it's arguably an ideal time for investors to seek the best breakout stocks for an explosive rally ahead.

News for Illumina Stock (ILMN)